EORTC‐18981

Trial name or title	Phase III randomized study of temozolomide with or without WBRT in patients with stage IV melanoma with asymptomatic brain metastases
Methods
Participants	1. histologically confirmed unresectable metastatic melanoma 2. concurrent visceral/soft tissue metastases 3. at least one site of measurable disease 4. documented evidence of disease progression 5. no neurologic symptoms
Interventions	Temozolomide chemotherapy versus temozolomide chemotherapy and WBRT
Outcomes	1. survival 2. time to appearance of neurologic symptoms 3. progression‐free survival 4. quality of life and quality‐adjusted survival 5. toxicity
Starting date	Closed
Contact information
Notes